inVentiv Clinical has expanded its global alliance with the additions of Protech Pharmaservices Corp. (PPC), Ecron Acunova and RDDA. These partnerships will broaden inVentiv Clinical Solutions’ clinical research capabilities in Latin America, Asia, Europe and Africa.

PPC, headquartered in Taiwan, has experience across Taiwan, Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia. The company provides drug development solutions, including Phase I – IV clinical study management, bioavailability/bioequivalence studies, central lab, data management and statistical analysis.

Ecron Acunova, headquartered in Frankfurt, Germany, operates across Europe, Asia and the Americas. The company provides services for Phase I – IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab for pharma/biotech, nutritional, medical diagnostic and device sponsors.

RDDA, a CRO based in Pretoria, South Africa, provides regulatory, project management and monitoring support across Africa including South Africa, Namibia, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.

“We are very pleased to welcome PPC, Ecron Acunova and RDDA to the inVentiv Clinical Global Alliance, which already includes ActivaCRO in Latin America. The expansion of our alliance is consistent with our mission to help clients accelerate quality clinical research in a cost-effective manner,” said Michael Hlinak, president and chief executive officer of inVentiv Clinical. “By forging alliances with these first-class partners, we are better positioned to provide our clients the unique, flexible solutions and unmatched quality they have come to expect from inVentiv Clinical, but on a global scale where it is needed today. Furthermore, this Global Alliance represents significant operational integration and access to rapidly developing clinical research markets.”